Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

210.42 +8.52 (+4.22%)
Streaming Delayed Price Updated: 11:04 AM EDT, Apr 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
News headline image
Natera to Present New Data from the CIRCULATE-Japan and BESPOKE CRC Studies at ASCO GI 2024 Supporting Signatera’s Clinical Utility in CRC
From Natera, Inc.
Via Business Wire
News headline image
Expert Ratings For Natera ↗
 
Via Benzinga
News headline image
Natera Hits A Nearly Two-Year High After Notching A Win In A Patent Battle ↗
The company must pay $57 million in damages, but that's far less than expected. 
Via Investor's Business Daily
Topics Intellectual Property
News headline image
Why DatChat Shares Are Trading Lower By Around 33%; Here Are 20 Stocks Moving Premarket ↗
Shares of DatChat, Inc. (NASDAQ: DATS) fell sharply in pre-market trading after announcing a proposed underwritten public offering of common stock. DatChat shares dipped 33.1% to $2.13 in pre-market... 
Via Benzinga
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Tuesday Morning
Via Investor Brand Network
News headline image
The Analyst Landscape: 8 Takes On Natera ↗
 
Via Benzinga
News headline image
The Latest Analyst Ratings for Natera ↗
 
Via Benzinga
News headline image
Progress Software Posts Strong Q4 Results, Joins Impinj, REGENXBIO And Other Big Stocks Moving Higher In Wednesday's Pre-Market Session ↗
U.S. stock futures were lower this morning, with the Dow Jones futures falling more than 100 points on Wednesday. Shares of Progress Software Corporation (NASDAQ: PRGS) rose in pre-market trading as... 
Via Benzinga
Topics Stocks
News headline image
Natera Provides Update on Ravgen Trial
From Natera, Inc.
Via Business Wire
News headline image
Bull of the Day - NeoGenomics ↗
But in late December, shares took a big hit on patent litigation with competitor Natera. Let's review the primary commercial business of NEO and then that will help put the legal news into context. 
Via Talk Markets
Topics Intellectual Property
News headline image
Natera Announces Preliminary Fourth Quarter and Full Year 2023 Revenues
From Natera, Inc.
Via Business Wire
News headline image
Analyst Expectations for Natera's Future ↗
 
Via Benzinga
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and warrant attention. 
Via Benzinga
News headline image
Expedia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Friday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
News headline image
Natera to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
From Natera, Inc.
Via Business Wire
News headline image
US Court Prohibits NeoGenomics To Sell Type Of Diagnostic Kits To Detect Smaller Number Of Cancer Cells, Favoring Natera In Lawsuit ↗
Shares of NeoGenomics Inc (NASDAQ: NEO) fell Thursday after the company received a preliminary injunction from a North Carolina district court, which prohibits the company from  
Via Benzinga
News headline image
Natera Wins Preliminary Injunction in Patent Infringement Lawsuit Against NeoGenomics’ RaDaR Test
From Natera, Inc.
Via Business Wire
News headline image
NATERA ALERT: Bragar Eagel & Squire, P.C. is Investigating Natera, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
News headline image
Natera Announces New Study Highlighting the Benefits of Signatera’s Unique Method of Quantifying ctDNA
From Natera, Inc.
Via Business Wire
News headline image
Delaware Court Denies CareDx’s Motion for Summary Judgment on Two Natera Patents
From Natera, Inc.
Via Business Wire
News headline image
Natera Presents New Signatera™ MRD Data Across Breast Cancer Treatment Settings at SABCS 2023
From Natera, Inc.
Via Business Wire
News headline image
Top 5 Health Care Stocks That May Collapse In November ↗
As of Nov. 17, 2023, five stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. 
Via Benzinga
News headline image
Natera Announces Real-World Data Collaboration with Merck
From Natera, Inc.
Via Business Wire
News headline image
Disney, Twilio, TransDigm, Marathon Digital And Other Big Stocks Moving Higher On Thursday ↗
U.S. stocks traded mostly lower, with the Dow Jones falling around 75 points on Thursday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Natera Reports Third Quarter 2023 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Natera Announces Randomized, Phase III TREAT ctDNA Trial in Early-Stage Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera to Participate in November Investor Conferences
From Natera, Inc.
Via Business Wire
News headline image
NATERA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
From Natera, Inc.
Via Business Wire
News headline image
Bull Of The Day: NeoGenomics ↗
NeoGenomics is a small-cap provider of cancer genetics diagnostics. They boast one of the most comprehensive oncology-focused testing menus in the world to help physicians diagnose and treat cancer. 
Via Talk Markets
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.